NIVOLUMAB\RELATLIMAB: 54 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
54
Total FAERS Reports
4 (7.4%)
Deaths Reported
9
Hospitalizations
54
As Primary/Secondary Suspect
3
Life-Threatening
2
Disabilities
First Report: 20220101 · Latest Report: 20240913
What Are the Most Common NIVOLUMAB\RELATLIMAB Side Effects?
#1 Most Reported
Secondary adrenocortical insufficiency
10 reports (18.5%)
#2 Most Reported
Off label use
6 reports (11.1%)
#3 Most Reported
Product storage error
3 reports (5.6%)
All NIVOLUMAB\RELATLIMAB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Secondary adrenocortical insufficiency | 10 | 18.5% | 0 | 0 |
| Off label use | 6 | 11.1% | 0 | 0 |
Who Reports NIVOLUMAB\RELATLIMAB Side Effects? Age & Gender Data
Gender: 28.6% female, 71.4% male. Average age: 69.7 years. Most reports from: US. View detailed demographics →
Is NIVOLUMAB\RELATLIMAB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2022 | 1 | 0 | 0 |
| 2023 | 1 | 0 | 1 |
| 2024 | 11 | 1 | 2 |
What Is NIVOLUMAB\RELATLIMAB Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 21 |
| Malignant melanoma | 11 |
| Metastatic malignant melanoma | 10 |
Official FDA Label for NIVOLUMAB\RELATLIMAB
Official prescribing information from the FDA-approved drug label.